Journament

Keyword Connections - hiv-1 Keywords

Connection Type	Connection
Journals	Organic & biomolecular chemistry European journal of medicinal chemistry Scientific reports Proceedings of the National Academy of Sciences of the United States of America Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases current pharmaceutical design annals of surgical oncology virus research journal der deutschen dermatologischen gesellschaft = journal of the german society of dermatology : jddg Journal of Virology archiv der pharmazie indian journal of pharmaceutical sciences retrovirology Antiviral research journal of experimental & clinical cancer research : cr il farmaco; edizione scientifica Protein expression and purification
Research Groups	No Research Group Connected
Bibliographies	[1] Molecular characteristic of HIV-1 CRF01_AE in Nanjing from 2015 to 2017. [2] Redefining Eligibility by Analyzing Canceled Intraoperative Radiotherapy as a Boost for Patients Undergoing Breast-Conserving Treatment. [3] Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity. [4] Differential neurodegenerative phenotypes are associated with heterogeneous voiding dysfunction in a coronavirus-induced model of multiple sclerosis. [5] cd8αα expression marks terminally differentiated human cd8+ t cells expanded in chronic viral infection [6] pathophysiology of cd4+ t-cell depletion in hiv-1 and hiv-2 infections [7] unexpected mutations in hiv-1 that confer resistance to the tat inhibitor didehydro-cortistatin a [8] microfluidic chip-based nucleic acid testing using gingival crevicular fluid as a new technique for detecting hiv-1 infection [9] a new role for the htlv-1 p8 protein: increasing intercellular conduits and viral cell-to-cell transmission [10] impact of the menstrual cycle on immunologic markers in hiv-infected taiwanese women [11] sensibilidade da técnica de reação em cadeia da polimerase para hiv-1 em relação à técnica de ensaio imunoenzimático [12] intrinsic immunity against retrotransposons by apobec cytidine deaminases [13] igm repertoire biodiversity is reduced in hiv-1 infection and systemic lupus erythematosus [14] inhibitors of hiv-1 reverse transcriptase—associated ribonuclease h activity [15] the cyp2b6 g516t polymorphism influences cd4+ t-cell counts in hiv-positive patients receiving antiretroviral therapy in an ethnically diverse region of the amazon [16] mangiferin, an anti-hiv-1 agent targeting protease and effective against resistant strains [17] diminished cd103 (aeb7) expression on resident t cells from the female genital tract of hiv-positive women [18] evaluation of a dry format reagent for cd4+ and cd8+ t-cell enumeration with facscount and guava polymerase chain reaction [19] natural killer cell interactions with classical and non-classical human leukocyte antigen class i in hiv-1 infection [20] role of nucleocytoplasmic rna transport during the life cycle of retroviruses [21] noncoding rnas and hiv: viral manipulation of host dark matter to shape the cellular environment [22] chapter 1. immunogenetics: genome wide association of non-progressive hiv and viral load control: hla genes and beyond [23] hiv, leukemia, and new horizons in molecular therapy [24] focus on chirality of hiv-1 non-nucleoside reverse transcriptase inhibitors [25] alkaloids from the sponge stylissa carteri present prospective scaffolds for the inhibition of human immunodeficiency virus 1 (hiv-1) [26] impact of hiv-1, hiv-2, and hiv-1+2 dual infection on the outcome of tuberculosis [27] differentially-expressed pseudogenes in hiv-1 infection [28] quantifying susceptibility of cd4+ stem memory t-cells to infection by laboratory adapted and clinical hiv-1 strains [29] fitness impaired drug resistant hiv-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency [30] recent 5-year findings and technological advances in the proteomic study of hiv-associated disorders [31] structural basis for the antiviral activity of bst-2/tetherin and its viral antagonism [32] unique flap conformation in an hiv-1 protease with high-level darunavir resistance [33] the nef activity on hiv-1 infectivity [34] hiv-1-infection of t lymphocytes and macrophages affects their migration via nef [35] structural and molecular determinants of hiv-1 gag binding to the plasma membrane [36] The expression of HIV-1 tat in Lactococcus lactis. [37] Glycosylation of the HIV-1 Env V1V2 loop to form a native-like structure may not be essential with a nanoparticle vaccine. [38] Novel 1,5-Diphenylpyrazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity versus the Delavirdine-Resistant P236L Mutant: Lead Identification and SAR of 3- and 4-Substituted Derivatives [39] Molecular Docking Study of Four Chromene Derivatives as Novel HIV-1 Integrase Inhibitors [40] Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project [41] HIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern Taiwan [42] High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014 [43] Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy [44] Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project [45] Evaluation of Anti-HIV-1 Integrase and Anti-Inflammatory Activities of Compounds from Betula alnoides Buch-Ham [46] HIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern Taiwan [47] High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014 [48] Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy [49] Investigating the distribution of HIV-1 Tat lengths present in the Drexel Medicine CARES cohort. [50] Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis. [51] The global spread of HIV-1 subtype B epidemic. [52] Increased Plasma Levels of the TH2 chemokine CCL18 associated with low CD4+ T cell counts in HIV-1-infected Patients with a Suppressed Viral Load [53] Feasibility of using dried blood spots for HIV viral load testing among HIV-infected individuals in Thailand using QIAGEN QIAsymphony-artus HIV-1 platform [54] Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults with Incident HIV-1 Infection [55] Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) [56] Inhibition of HIV-1 envelope-dependent membrane fusion by serum antilymphocyte autoantibodies is associated with low plasma viral load [57] AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region. [58] HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. [59] Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. [60] Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice. [61] A short-term assessment of nascent HIV-1 transmission clusters among newly diagnosed individuals using envelope sequence-based phylogenetic analyses. [62] Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. [63] Methamphetamine functions as a novel CD4<sup>+</sup> T-cell activator via the sigma-1 receptor to enhance HIV-1 infection [64] A SYSTEMATIC REVIEW ON THE INFLUENCE OF HLA-B POLYMORPHISMS ON HIV-1 MOTHER-TO-CHILD-TRANSMISSION. [65] Perinatal HIV-1 transmission: Fc gamma receptor variability associates with maternal infectiousness and infant susceptibility. [66] Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. [67] Epidemiology of HIV-1 infection in agricultural plantation residents in Kericho, Kenya: preparation for vaccine feasibility studies. [68] Targeting HIV-1 Protease Autoprocessing for High-throughput Drug Discovery and Drug Resistance Assessment [69] Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors [70] Identification of a large, fast-expanding HIV-1 subtype B transmission cluster among MSM in Valencia, Spain. [71] Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations. [72] Association of circulatory Tfh-like cells with neutralizing antibody responses among chronic HIV-1 subtype C infected long-term nonprogressors and progressors. [73] Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket [74] Molecular characteristic of HIV-1 CRF01_AE in Nanjing from 2015 to 2017. [75] Design and Biological Evaluation of m-Xylene Thioether-stapled Short Helical Peptides Targeting the HIV-1 gp41 Hexameric Coiled-Coil Fusion Complex. [76] Correction: Conformational states of HIV-1 reverse transcriptase for nucleotide incorporation vs pyrophosphorolysis - Binding of Foscarnet (ACS Chemical Biology (2016) 11: 8 (2158-2164) DOI: 10.1021/acschembio.6b00187) [77] Use of Dried Blood Spots to Elucidate Full-Length Transmitted/Founder HIV-1 Genomes [78] Transmission dynamics of HIV-1 subtype B strains in Indonesia. [79] Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study. [80] Contribution of the Microbiota to Intestinal Homeostasis and its Role in the Pathogenesis of HIV-1 Infection. [81] Enzymatic Glycosylation of Triazole-Linked GlcNAc/Glc-Peptides: Synthesis, Stability and Anti-HIV Activity of Triazole-Linked HIV-1 gp41 Glycopeptide C34 Analogues [82] Synthesis of novel benzofuran and related benzimidazole derivatives for evaluation ofin vitro anti-HIV-1, anticancer and antimicrobial activities [83] Large transmission clusters of HIV-1 main genotypes among HIV-1 individuals before antiretroviral therapy in the Hebei province, China. [84] Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment. [85] Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120. [86] Performance of an Alternative Laboratory-Based HIV Diagnostic Testing Algorithm Using HIV-1 RNA Viral Load. [87] Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4–8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011–12 and 2012–13 [88] Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance. [89] Epidemiology of transmitted drug resistance mutations in an HIV-1 subtype C high-prevalence setting and impact on 1-year virological failure [90] Stability behaviour of antiretroviral drugs and their combinations. 11: Characterization of interaction products of zidovudine and efavirenz, and evaluation of their anti HIV-1 activity, and physiochemical and ADMET properties [91] Proton transfer and drug binding details revealed in neutron diffraction studies of wild-type and drug resistant HIV-1 protease [92] Following the path: Increasing trends of HIV-1 drug resistance in China [93] Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001–2017) [94] (Q)SAR Models of HIV-1 protein inhibition by drug-like compounds [95] Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection [96] Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance [97] Semen Extracellular Vesicles From HIV-1-Infected Individuals Inhibit HIV-1 Replication In Vitro, and Extracellular Vesicles Carry Antiretroviral Drugs In Vivo [98] Forecasting Prevalence of HIV-1 Integrase Strand Transfer Inhibitor (INSTI) Drug Resistance: A Modeling Study [99] Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection. [100] Discovery of dihydroxyindole-2-carboxylic acid derivatives as dual allosteric HIV-1 Integrase and Reverse Transcriptase associated Ribonuclease H inhibitors. [101] Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity.